Europe Drug Screening Market

Europe Drug Screening Market Size (2022 to 2027)

The size of the Europe Drug Screening Market is valued at USD 1.74 billion in 2022. It is expected to grow at a CAGR of 9.40% to approach USD 2.73 billion by 2027.

Rising drug abuse among the European countries, increasing alcohol consumption and illicit drugs, growing funds from the government to control drug marketing, rising awareness regarding the drug screening policy are majorly supporting and accelerating the drug screening market in Europe. An estimated 3.3 million people are dying due to the deadly effects of alcohol and almost half of the deaths are avoidable with developing, organizing, monitoring, and evaluation of treatment and other services. Growing competition and an increasing number of mergers and acquisitions between the market participants are expected to offer new growth possibilities in the near future.

Strict laws and ban on alcohol consumption in the European countries are expected to restrain the market to a limited extent during the forecast period. Drug screening is considered as an offense of privacy rights, accuracy issues with breathalyzers are restraining the market growth during the analysis period.

This research report on the Europe Drug Screening Market has been segmented and sub-segmented into the following categories:

• By Sample Type: Hair, Blood, Urine, and Others
• By End-user: Hospitals, Workplaces, Criminal Justice & Law Enforcement
• By Products And Services: Breathalyser, Rapid Test Device, Immunoassay Analyser, Chromatography, Others
• By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, and Rest of Europe

Regional Analysis:

The European market proved to be the second-highest market among all the regions in terms of the market share that contributed to the global market. This trend is predicted to be continued in the future as well, majorly because of the enactment of new and more stringent regulations by the governments of several countries in the region.

The drug screening market in the UK was accounted for the leading share in the European market due to the surging consciousness on the people’s health, new technology inventions that provide exact and correct results.

France and Germany are expected to have quick growth in the market. Development and obtaining of new procedures and methods along with devices towards drug screening are predicted to offer some crucial opportunities in the market, immense usage of drug screening activities particularly in railways, transport, and airline sector is expected to dominate the market growth.

Key players operating in the Europe Drug Screening Market profiled in this report are Thermo Fisher Scientific Inc., Express Diagnostics Int’l Inc., Abbott Laboratories, Siemens AG, Alere Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Biorad Laboratories Inc., Shimadzu and Omega Laboratories.